Skip to Content
  • Previous Rank187
  • Country
  • Revenues ($M)$53,647.00
  • Revenue Percent Change2.1%
  • Profits ($M)$11,153.00
  • Profits Percent Change-47.7%
  • Assets ($M)$159,422.00
  • Employees92,400

In Ian Read’s final year as the company’s CEO, Pfizer managed to grow revenues by just 2% as it adjusted to greater competition to—and diminished sales of—Viagra and other drugs on which the company lost patent exclusivity in 2017. The pharmaceutical giant is now in the midst of a reorganization since announcing in the summer of 2018 that it would separate its business into three parts, one of which (its consumer health division) it plans to merge into a joint venture with GlaxoSmithKline. The moves are designed to position Pfizer for greater sales growth under new CEO Albert Bourla.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Information

Albert Bourla
Health Care
HQ Location
New York City
Years on Global 500 List25

Pfizer Rank History

Key Financials (Last Fiscal Year)

($ Millions)% change
Revenues ($M)$53,647.002.1%
Profits ($M)$11,153.00-47.7%
Assets ($M)$159,422.00-
Total Stockholder Equity ($M)$63,407.00-

Profit Ratios

Profit as % of Revenues20.8%
Profits as % of Assets7%
Profits as % of Stockholder Equity17.6%